Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1997 Apr 15;323(Pt 2):371–377. doi: 10.1042/bj3230371

Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.

N T Dickinson 1, E K Jang 1, R J Haslam 1
PMCID: PMC1218329  PMID: 9163326

Abstract

cGMP enhances cAMP accumulation in platelets via cGMP-inhibited phosphodiesterase (PDE3) [Maurice and Haslam (1990) Mol. Pharmacol. 37, 671-681]. However, cGMP might also limit cAMP accumulation by activating cGMP-stimulated phosphodiesterase (PDE2). We therefore evaluated the role of PDE2 in human platelets by using erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) to inhibit this enzyme selectively. IC50 values for the inhibition of platelet PDE2 by EHNA, with 10 microM cAMP as substrate in the absence and in the presence of 1 microM cGMP, were 15 and 3 microM respectively. Changes in platelet cyclic [3H]nucleotides were measured after prelabelling with [3H]adenine and [3H]guanine. Nitroprusside (NP) caused concentration-dependent increases in [3H]cGMP and a biphasic increase in [3H]cAMP, which was maximal at 10 microM (49+/-6%) and smaller at 100 microM (32+/-6%) (means+/-S.E.). In the presence of EHNA (20 microM), which had no effects alone, NP caused much larger increases in platelet [3H]cAMP (125+/-14% at 100 microM). EHNA also enhanced [3H]cGMP accumulation at high NP concentrations. In accord with these results, EHNA markedly potentiated the inhibition of thrombin-induced platelet aggregation by NP. The roles of cAMP and cGMP in this effect were investigated by using 2', 5'-dideoxyadenosine to inhibit adenylate cyclase. This compound decreased the accumulation of [3H]cAMP but not that of [3H]cGMP, and diminished the inhibition of platelet aggregation by NP with EHNA. We conclude that much of the effect of NP with EHNA is mediated by cAMP. Lixazinone (1 microM), a selective inhibitor of PDE3, increased platelet [3H]cAMP by 177+/-15%. This increase in [3H]cAMP was markedly inhibited by NP; EHNA blocked this effect of NP. Parallel studies showed that NP suppressed the inhibition of platelet aggregation by lixazinone. EHNA enhanced the large increases in [3H]cAMP seen with 20 nM prostacyclin (PGI2), but had no effect with 1 nM PGI2. NP and 1 nM PGI2 acted synergistically to increase [3H]cAMP, an effect attributable to the inhibition of PDE3 by cGMP; EHNA greatly potentiated this synergism. In contrast, NP decreased the [3H]cAMP accumulation seen with 20 nM PGI2, an effect that was blocked by EHNA. The results show that, provided that cGMP is present, PDE2 plays a major role in the hydrolysis of low cAMP concentrations and restricts any increases in cAMP concentration and decreases in platelet aggregation caused by the inhibition of PDE3. At high cAMP, PDE2 plays the major role in cAMP breakdown, whether cGMP is present or not.

Full Text

The Full Text of this article is available as a PDF (528.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anfossi G., Massucco P., Piretto V., Mularoni E., Cavalot F., Mattiello L., Trovati M. Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Clin Exp Pharmacol Physiol. 1995 Nov;22(11):803–811. doi: 10.1111/j.1440-1681.1995.tb01939.x. [DOI] [PubMed] [Google Scholar]
  2. Beavo J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995 Oct;75(4):725–748. doi: 10.1152/physrev.1995.75.4.725. [DOI] [PubMed] [Google Scholar]
  3. Davis C. W., Daly J. W. A simple direct assay of 3',5'-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-bononate affinity gel chromatography. J Cyclic Nucleotide Res. 1979;5(1):65–74. [PubMed] [Google Scholar]
  4. Eigenthaler M., Nolte C., Halbrügge M., Walter U. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem. 1992 Apr 15;205(2):471–481. doi: 10.1111/j.1432-1033.1992.tb16803.x. [DOI] [PubMed] [Google Scholar]
  5. Fisch A., Michael-Hepp J., Meyer J., Darius H. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur J Pharmacol. 1995 May 26;289(3):455–461. doi: 10.1016/0922-4106(95)90154-x. [DOI] [PubMed] [Google Scholar]
  6. Grant P. G., Mannarino A. F., Colman R. W. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets. Thromb Res. 1990 Jul 1;59(1):105–119. doi: 10.1016/0049-3848(90)90276-i. [DOI] [PubMed] [Google Scholar]
  7. Grünberg B., Negrescu E., Siess W. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost. Eur J Pharmacol. 1995 Feb 15;288(3):329–333. doi: 10.1016/0922-4106(95)90045-4. [DOI] [PubMed] [Google Scholar]
  8. Halbrügge M., Friedrich C., Eigenthaler M., Schanzenbächer P., Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J Biol Chem. 1990 Feb 25;265(6):3088–3093. [PubMed] [Google Scholar]
  9. Haslam R. J., Davidson M. M., Davies T., Lynham J. A., McClenaghan M. D. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Res. 1978;9:533–552. [PubMed] [Google Scholar]
  10. Haslam R. J., Davidson M. M., Desjardins J. V. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J. 1978 Oct 15;176(1):83–95. doi: 10.1042/bj1760083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Haslam R. J., Rosson G. M. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol. 1975 Sep;11(5):528–544. [PubMed] [Google Scholar]
  12. Haynes J., Jr, Killilea D. W., Peterson P. D., Thompson W. J. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. J Pharmacol Exp Ther. 1996 Feb;276(2):752–757. [PubMed] [Google Scholar]
  13. Hidaka H., Asano T. Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta. 1976 Apr 8;429(2):485–497. doi: 10.1016/0005-2744(76)90296-5. [DOI] [PubMed] [Google Scholar]
  14. Horstrup K., Jablonka B., Hönig-Liedl P., Just M., Kochsiek K., Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994 Oct 1;225(1):21–27. doi: 10.1111/j.1432-1033.1994.00021.x. [DOI] [PubMed] [Google Scholar]
  15. Jiang H., Shabb J. B., Corbin J. D. Cross-activation: overriding cAMP/cGMP selectivities of protein kinases in tissues. Biochem Cell Biol. 1992 Dec;70(12):1283–1289. doi: 10.1139/o92-175. [DOI] [PubMed] [Google Scholar]
  16. Levin R. I., Weksler B. B., Jaffe E. A. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function. Circulation. 1982 Dec;66(6):1299–1307. doi: 10.1161/01.cir.66.6.1299. [DOI] [PubMed] [Google Scholar]
  17. MacFarland R. T., Zelus B. D., Beavo J. A. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem. 1991 Jan 5;266(1):136–142. [PubMed] [Google Scholar]
  18. Martins T. J., Mumby M. C., Beavo J. A. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem. 1982 Feb 25;257(4):1973–1979. [PubMed] [Google Scholar]
  19. Maurice D. H., Haslam R. J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990 May;37(5):671–681. [PubMed] [Google Scholar]
  20. Maurice D. H., Lee R. M., Haslam R. J. Measurement of both cyclic [3H]AMP and cyclic [3H]GMP in cultured vascular smooth muscle cells labeled with [3H]hypoxanthine: use in studies of cardiovascular drugs. Anal Biochem. 1993 Nov 15;215(1):110–117. doi: 10.1006/abio.1993.1562. [DOI] [PubMed] [Google Scholar]
  21. Mellion B. T., Ignarro L. J., Ohlstein E. H., Pontecorvo E. G., Hyman A. L., Kadowitz P. J. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981 May;57(5):946–955. [PubMed] [Google Scholar]
  22. Mustard J. F., Perry D. W., Ardlie N. G., Packham M. A. Preparation of suspensions of washed platelets from humans. Br J Haematol. 1972 Feb;22(2):193–204. doi: 10.1111/j.1365-2141.1972.tb08800.x. [DOI] [PubMed] [Google Scholar]
  23. Méry P. F., Pavoine C., Pecker F., Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol. 1995 Jul;48(1):121–130. [PubMed] [Google Scholar]
  24. Radomski M. W., Palmer R. M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987 Nov;92(3):639–646. doi: 10.1111/j.1476-5381.1987.tb11367.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Reeves M. L., Leigh B. K., England P. J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J. 1987 Jan 15;241(2):535–541. doi: 10.1042/bj2410535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schaeffer H. J., Schwender C. F. Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J Med Chem. 1974 Jan;17(1):6–8. doi: 10.1021/jm00247a002. [DOI] [PubMed] [Google Scholar]
  27. Tang K. M., Sherwood J. L., Haslam R. J. Photoaffinity labelling of cyclic GMP-binding proteins in human platelets. Biochem J. 1993 Sep 1;294(Pt 2):329–333. doi: 10.1042/bj2940329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Whalin M. E., Scammell J. G., Strada S. J., Thompson W. J. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells. Mol Pharmacol. 1991 Jun;39(6):711–717. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES